OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
28
Results
Show all
Save search
Copy query
Show results for
Unknown
(28)
Release Date
2019
(5)
2017
(4)
2020
(3)
2018
(3)
2016
(3)
2015
(3)
2022
(2)
2024
(1)
2023
(1)
2021
(1)
2009
(1)
2007
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.
Not available
S-EPMC6369924
|
biostudies-literature
Cite
Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes.
Not available
S-EPMC5806098
|
biostudies-literature
Cite
Dihydronicotinamide Riboside Is a Potent NAD
+
Precursor Promoting a Pro-Inflammatory Phenotype in Macrophages.
Not available
S-EPMC8913500
|
biostudies-literature
Cite
Immunophenotyping of Waldenstroms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.
Not available
S-EPMC4390194
|
biostudies-literature
Cite
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.
Not available
S-EPMC5569902
|
biostudies-literature
Cite
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Not available
S-EPMC4566809
|
biostudies-literature
Cite
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Not available
S-EPMC2200918
|
biostudies-literature
Cite
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
Not available
S-EPMC5321078
|
biostudies-literature
Cite
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.
Not available
S-EPMC11377826
|
biostudies-literature
Cite
Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis.
Not available
S-EPMC6058787
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
